Improved plasma stability and sustained release profile of gemcitabine via polypeptide conjugation

International Journal of Pharmaceutics

Volumn 391, Issue 1-2, 2010, Pages 212-220

  Kiew, Lik Voon ^a   Cheong, Soon Keng ^b   Sidik, Khalifah ^c   Chung, Lip Yong ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Gemcitabine; Poly l glutamic acid; Polymeric drug conjugates; Sustained release

Indexed keywords

CYANAMIDE; GEMCITABINE; POLYGLUTAMIC ACID; POLYGLUTAMIC ACID GEMCITABINE CONJUGATE; POLYMER; POLYPEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN MCF 7; CHEMICAL REACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DEGRADATION; DRUG PURIFICATION; DRUG PURITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; FIBROBLAST CULTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DEOXYCYTIDINE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; FEMALE; HUMANS; POLYGLUTAMIC ACID; PRODRUGS;

EID: 77952884118     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.03.010     Document Type: Article

References (49)

1. Abbruzzese J.L., Grunewald R., Weeks E.A., Gravel D., Adams T., Nowak B., Mineishi S., Tarassoff P., Satterlee W., Raber M.N. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J. Clin. Oncol. 1991, 9:491-498.
2. Abratt R.P. Gemcitabine hydrochloride: combination of activity and tolerability. Anticancer Drugs 1995, 6:63-64.
3. Aslakson C.J., Miller F.R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992, 52:1399-1405.
4. Bates S.E., Valverius E.M., Ennis B.W., Bronzert D.A., Sheridan J.P., Stampfer M.R., Mendelsohn J., Lippman M.E., Dickson R.B. Expression of the transforming growth factor-α/epidermal growth factor receptor pathway in normal human breast epithelial cells. Endocrinology 1990, 126:596-607.
5. Batz H.G., Ringsdorf H., Ritter H. Pharmacologically active polymers, 7. Cyclophosphamide- and steroid hormone-containing polymers as potential anticancer compounds. Makromol. Chem. 1974, 175:2229-2239.
6. Cavallaro G., Mariano L., Salmaso S., Caliceti P., Gaetano G. Folate-mediated targeting of polymeric conjugates of gemcitabine. Int. J. Pharm. 2006, 307:258-269.
7. Celano M., Calvagno M.G., Bulotta S., Paolino D., Arturi F., Rotiroti D., Filetti S., Fresta M., Russo D. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer 2004, 4:63-68.
8. Duncan R., Gac-Breton S., Keane R., Musila R., Sat Y.N., Satchi R., Searle F. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Control. Release 2001, 74:135-146.
9. Duncan R., Spreafico F. Polymer conjugates, pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 1994, 27:290-306.
10. Duncan R., Vicent M.J., Greco F., Nicholson R.I. Polymer-drug conjugates: towards a novel approach for the treatment of endocrine-related cancer. Endocr. Relat. Cancer 2005, 12(Suppl. 1):S189-S199.
11. Egorin M.J., Zuhowski E.G., McCully C.M., Blaney S.M., Kerr J.Z., Berg S.L., Balis F.M. Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. Clin. Cancer Res. 2002, 8:2437-2442.
12. Fossella F.V., Lippman S.M., Shin D.M., Tarassoff P., Calayag-Jung M., Perez-Soler R., Lee J.S., Murphy W.K., Glisson B., Rivera E., Hong W.K. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 1997, 15:310-316.
13. Fowler W.C., Van Le L. Gemcitabine as a single-agent treatment for ovarian cancer. Gynecol. Oncol. 2003, 90(Suppl. 1):S21-S23.
14. Garnett M.C. Targeted drug conjugates: principles and progress. Adv. Drug Deliv. Rev. 2001, 53:171-216.
15. Haller D.G. Chemotherapy for advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56(Suppl. 1):16-23.
16. Harper P. Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer. Semin. Oncol. 2003, 30(Suppl. 10):2-12.
17. Hoes C.J.T., Grootoonk J., Duncan R., Hume I.C., Bhakoo M., Bouma J.M.W., Feijen J. Biological properties of the adriamycin bound to biodegradable polymeric carriers. J. Control. Release 1993, 23:37-54.
18. Hoes C.J.T., Potman W., van Heeswijk W.A.R., Mud J., de Grooth B.G., Greve J., Feijen J. Optimization of macromolecular prodrugs of the antibiotic adriamycin. J. Control. Release 1986, 2:205-213.
19. Hurwitz E., Wilchek M., Pitha J. Soluble macromolecules as carriers for daunorubicin. J. Appl. Biochem. 1980, 2:25-35.
20. Immordino M.L., Brusa P., Rocco F., Arpicco S., Ceruti M., Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J. Control. Release 2004, 100:331-346.
21. Jansen P.J., Akers M.J., Amos R.M., Baertschi S.W., Cooke G.G., Dorman D.E., Kemp C.A.J., Maple S.R., McCune K.A. The degradation of the antitumour agent gemcitabine hydrochloride in an acidic aqueous solution at pH 3.2 and identification of degradation products. J. Pharm. Sci. 2000, 89:885-891.
22. Kato Y., Saito M., Fukushima H., Takeda Y., Hara T. Antitumor activity of 1-β-d-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative. Cancer Res. 1984, 44:25-30.
23. Kopecek J. The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery. J. Control. Release 1990, 11:279-290.
24. Kwak I.H., Kim S.H., Choi O.R., Ryu M.S., Lim I.K. Nuclear accumulation of globular actin as a cellular senescence marker. Cancer Res. 2004, 64:572-580.
25. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
26. Li C. Poly(l-glutamic acid)-anticancer drug conjugates. Adv. Drug Deliv. Rev. 2002, 54:695-713.
27. Li C., Price J.E., Milas L., Hunter N.R., Ke S., Yu D.-F., Charnsangavej C., Wallace S. Antitumor activity of poly(l-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin. Cancer Res. 1999, 5:891-897.
28. Li C.-Y., Shan S., Huang Q., Braun R.D., Lanzen J., Hu K., Lin P., Dewhirst M.W. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J. Natl. Cancer Inst. 2000, 92:143-147.
29. Li., C., Wallace, S., Yu, D.-F., Yang, D.J., 2002. Water soluble paclitaxel derivatives. US Patent 6,441,025.
30. Li C., Yu D.-F., Newman R.A., Cabral F., Stephens L.C., Hunter N., Milas L., Wallace S. Complete regression of well-established tumors using a novel water-soluble poly(l-glutamic acid)-paclitaxel conjugate. Cancer Res. 1998, 58:2404-2409.
31. Lund B., Kristjansen P.E., Hansen H.H. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat. Rev. 1993, 19:45-55.
32. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 1991, 46:169-185.
33. Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 1989, 6:193-210.
34. Merck Index 13th ed., 2001. Merck & Co., Inc, USA, Monograph No. 4397.
35. Merrill C.R., Goldmann D., van Keuren M.L. Silver staining methods for polyacrylamide gel electrophoresis. Methods in Enzymology 1983, vol. 96:17. Academic Press, New York.
36. Mochizuki E., Inaki Y., Takemoto K. Synthesis of poly-l-glutamates containing 5-substituted uracil moieties. Nucleic Acids Symp. Ser. 1985, 16:121-124.
37. Morimoto Y., Sugibayashi K., Sugihara S., Hosoya K., Nozaki S., Ogawa Y. Antitumor agent poly (amino acid) conjugates as a drug carrier in chemotherapy. J. Pharmacobiodyn. 1984, 7:688-698.
38. Myhren, F., Borretzen, B., Dalen, A., Sandvold, M., 1998. Gemcitabine derivatives. WO Patent 98/32762.
39. Noble S., Goa K.L. Gemcitabine. A review of its pharmacological and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997, 54:447-472.
40. Oldham E.A., Li C., Ke S., Wallace S., Huang P. Comparison of action of paclitaxel and poly (l-glutamic acid)-paclitaxel conjugate in human breast cancer cells. Int. J. Oncol. 2000, 16:125-132.
41. Plunkett W., Huang P., Searcy C.E., Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin. Oncol. 1996, 23(Suppl. 10):3-15.
42. Pulaski B.A., Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 1998, 58:1486-1493.
43. Reynolds T. Polymers help guide cancer drugs to tumor targets-and keep them there. J. Natl. Cancer Inst. 1995, 87:1582-1584.
44. Singer J.W., Bhatt R., Tulinsky J., Buhler K.R., Heasley E., Klein P., de Vries P. Water soluble poly-(l-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J. Control. Release 2001, 74:243-247.
45. Singer J.W., Devries P., Bhatt R., Tulinsky J., Klein P., Li C., Milas L., Lewis R.A., Wallace S. Conjugation of camptothecin to poly-(l-glutamic acid). Ann. N. Y. Acad. Sci. 2000, 922:136-150.
46. Van Dijk M.A.J., Floore A.N., Kloppenborg K.I.M., van't Veer L.J. A functional assay in yeast for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma. Cancer Res. 1997, 57:3478-3485.
47. Xu Q., Zhang Y., Trissel L.A. Physical and chemical stability of gemcitabine hydrochloride solutions. J. Am. Pharm. Assoc. (Wash.) 1999, 39:509-513.
48. Zou Y., Wu Q.P., Tansey W., Chow D., Hung M.C., Charnsangavej C., Wallace S., Li C. Effectiveness of water soluble poly(l-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice. Int. J. Oncol. 2001, 18:331-336.
49. Zunino F., Pratesi G., Micheloni A. Poly(carboxylic acid) polymers as carriers for anthracyclines. J. Control. Release 1989, 10:65-73.